GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Selling, General, & Admin. Expense

Sinopharm Group Co (Sinopharm Group Co) Selling, General, & Admin. Expense : $1,905 Mil (TTM As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Sinopharm Group Co's selling, general, & admin. expense for the three months ended in Sep. 2023 was $785 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2023 was $1,905 Mil.


Sinopharm Group Co Selling, General, & Admin. Expense Historical Data

The historical data trend for Sinopharm Group Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Selling, General, & Admin. Expense Chart

Sinopharm Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,775.88 3,240.65 3,642.24 3,572.03 3,662.33

Sinopharm Group Co Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 805.99 1,120.02 - 784.95 -

Competitive Comparison of Sinopharm Group Co's Selling, General, & Admin. Expense

For the Medical Distribution subindustry, Sinopharm Group Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's Selling, General, & Admin. Expense Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Selling, General, & Admin. Expense falls into.



Sinopharm Group Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,905 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Sinopharm Group Co Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co (Sinopharm Group Co) Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (Sinopharm Group Co) Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021